➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,265,893

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,265,893 protect, and when does it expire?

Patent 9,265,893 protects VICTOZA and is included in one NDA.

Protection for VICTOZA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in thirteen countries.

Summary for Patent: 9,265,893
Title:Injection button
Abstract: A push button connection for an injection device comprising a push button (10) and a driving part (20). The two parts of the push button connection are mounted to each other and is relatively rotatable to each other. In order to minimize the friction occurring between the push button and the driving part when relatively rotated forces are transmitted via a pivot bearing (18, 22). In order also to minimize the effect of forces appearing dislocated from the center line a number of radial bearings (13, 23; 14, 25) having a little friction diameter is provided.
Inventor(s): Hansen; Torben Stroem (Copenhagen V, DK), Wielandt; Jakob Oest (Copenhagen N, DK), Groth; Lars Moerch (Fredensborg, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:12/525,976
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,265,893
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,265,893

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo Nordisk Inc VICTOZA liraglutide recombinant SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,265,893

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07101729Feb 5, 2007
PCT Information
PCT FiledJanuary 21, 2008PCT Application Number:PCT/EP2008/050624
PCT Publication Date:August 14, 2008PCT Publication Number: WO2008/095762

International Family Members for US Patent 9,265,893

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 483487   Start Trial
Australia 2008213084   Start Trial
Brazil PI0806854   Start Trial
Canada 2676810   Start Trial
China 101605569   Start Trial
Germany 602008002896   Start Trial
Denmark 2109474   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.